Trial Profile
A PHASE 1/2, OPEN-LABEL, SINGLE ARM TRIAL TO DETERMINE THE RECOMMENDED PHASE 2 DOSE AND EVALUATE THE EFFICACY OF PF-00299804 IN PATIENTS IN KOREA WITH KRAS WILD TYPE ADVANCED NSCLC, WHICH IS REFRACTORY TO CHEMOTHERAPY AND ERLOTINIB OR GEFITINIB
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 07 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Aug 2013 Planned End Date changed from 1 Aug 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 23 Jul 2013 Planned end date changed from 1 Dec 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.